|1.||Burgess, Michael: 2 articles (04/2007 - 07/2004)|
|2.||Briglia, Marilena: 1 article (01/2015)|
|3.||Faggio, Caterina: 1 article (01/2015)|
|4.||Lang, Florian: 1 article (01/2015)|
|5.||Fazio, Antonella: 1 article (01/2015)|
|6.||Sane, Rucha: 1 article (05/2012)|
|7.||Podila, Lalitha: 1 article (05/2012)|
|8.||Mease, Kirsten: 1 article (05/2012)|
|9.||Taub, Mitchell E: 1 article (05/2012)|
|10.||Harpstrite, Scott E: 1 article (07/2010)|
09/15/1996 - "Treatment of mice bearing P388/ADR murine leukemia cells with LY335979 in combination with Dox or etoposide gave a significant increase in life span with no apparent alteration of pharmacokinetics. "
05/01/1995 - "RS-33295-198 modulated doxorubicin resistance in a murine P388/ADR leukemia model when administered ip via continuous minipump delivery, ip by bolus injection, and orally; it also improved the efficacy of vincristine toward P388/VCR leukemia when given ip or po. "
|2.||Sarcoma (Soft Tissue Sarcoma)
|3.||Breast Neoplasms (Breast Cancer)
09/01/2009 - "A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen."
05/01/2012 - "Caco-2 and MDCK-MDR1 cells were used to evaluate the selectivity of zosuquidar (LY335979), fumitremorgin C (FTC), and MK571 as inhibitors of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and multidrug resistance-associated protein 2 (MRP2), respectively. "
01/01/2003 - "Our study examines the ability of LY335979 (Zosuquidar trihydrochloride) to modulate 3 distinct ABC transporters that are mechanisms of drug resistance: P-glycoprotein (Pgp, ABCB1), multidrug resistance associated protein (MRP1, ABCC2) and breast cancer resistance protein (BCRP, ABCG2). "
|4.||Non-Hodgkin Lymphoma (Lymphosarcoma)
01/01/1997 - "These desirable features strongly suggest that LY335979 is an exciting new clinical agent to test the hypothesis that inhibition of P-glycoprotein activity will result in reversal of multidrug resistance in human tumors."
01/01/1998 - "Compound LY335979 is a P-glycoprotein inhibitor currently entering phase I clinical trials for potential reversal of multidrug resistance to cancer chemotherapy. "
01/01/2001 - "Coadministration of LY335979 with paclitaxel compared to paclitaxel alone significantly reduced the tumor mass of the Pgp-expressing UCLA-P3.003VLB lung carcinoma in a xenograph model and delayed the development of tumors in mice implanted with the parental drug-sensitive UCLA-P3 tumor. "
01/01/2015 - "The P-glycoprotein inhibitor zosuquidar (LY335979) is clinically used to augment the effect of cytostatic drugs on suicidal tumor cell death or apoptosis. "
01/01/2003 - "These results further demonstrate that LY335979 is highly specific for Pgp and does not modulate MRP1- or BCRP-mediated resistance and can be used in combination with mitoxantrone and vinorelbine in tumor cells."
|4.||zosuquidar trihydrochloride (LY335979)
|5.||Multidrug Resistance-Associated Proteins
|6.||ATP-Binding Cassette Transporters (ABC Transporters)
|10.||Etoposide (VP 16)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)